Invesco’s Jasper Therapeutics JSPR Stock Holding History

Invesco’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-19,121	Closed	-$434K	–	3820
2024 Q2	$434K	Buy	+19,121	New	+$459K	﹤0.01%	3336

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco's JSPR Position: Q3 2024 in Review

Invesco sold out of Jasper Therapeutics (JSPR) in Q3 2024, closing a stake of 19,121 shares — an estimated $434K sold.

Invesco first reported a position in JSPR in Q2 2024 and held it in 1 quarter. The position peaked at $434K in Q2 2024. 81 funds tracked by Wall St. Rank hold JSPR as of Q3 2024.

Invesco reported no remaining Jasper Therapeutics position as of Q3 2024 after selling out during the quarter.
Invesco sold 19,121 Jasper Therapeutics shares in Q3 2024, an estimated $434K.
Invesco first reported a position in Jasper Therapeutics in Q2 2024 and held it in 1 quarter.
Invesco's Jasper Therapeutics position peaked at $434K in Q2 2024.
81 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2024.

Based on Invesco's 13F filing for Q3 2024, filed 12 Nov 2024.